Business
32 Biosciences to Launch $40 Million Series A at J.P. Morgan to Advance First-in-Class GI Mucosal-Immune Therapeutics
NORTH CHICAGO, Ill., January 08, 2026--32 Biosciences to launch $40M Series A at JPM 2026, advancing CS-0003 mucosal-immune therapies for GI SSI and the GB platform.
About this update from Jp Morgan Chase & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":288,"url":"https://media.zenfs.com/en/business-wire.com/ad7b4f1923e454ebd65bd684fc761e23"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YE1dTLpzF5O7qIVvI6drGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU3NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ad7b4f1923e454ebd65bd684fc761e23","width":480,"height":288}},"lazy":false},{"type":"text","content":"Series A expected to advance lead asset Mucosal-Immune Modulator CS-0003 through Phase II in GI surgical site infections and expand a differentiated GI mucosal-immune pipeline and metabolomics-driven discovery platform","length":218,"tagName":"p"},{"type":"text","content":"NORTH CHICAGO, Ill., January 08, 2026--(BUSINESS WIRE)--32 Biosciences, a gastrointestinal (GI)-focused biotechnology company pioneering gut mucosal-immune science to prevent and treat GI diseases, today announced that it will officially launch its $40 million Series A financing during the 2026 J.P. Morgan Healthcare Conference (January 12–15, 2026).","length":352,"tagName":"p"},{"type":"text","content":"The Series A financing is intended to advance CS-0003, a first-in-class Mucosal-Immune Modulator (MIM) designed to buffer the GI tract by coating and protecting the mucosal barrier, suppressing bacterial virulence, and modulating the mucosal-immune system. The lead indication is prevention of gastrointestinal surgical site infections (GI SSI), with potential expansion into inflammatory bowel disease (IBD) and prevention of colon cancer recurrence, where mucosal barrier dysfunction and immune dysregulation play a central role.","length":531,"tagName":"p"},{"type":"text","content":""Launching our Series A at JPM is a key step as we advance CS-0003 into the clinic and build our GB discovery platform," said Peter Farmakis, Chairman & Chief Executive Officer of 32 Biosciences. "We’re restoring and protecting the gut mucosal-immune system—an overlooked but central driver of surgical outcomes and chronic disease—with the goal of meaningfully improving outcomes for patients facing serious GI disease."","length":445,"tagName":"p"},{"type":"text","content":"A differentiated therapeutic and platform built around gut mucosal-immune biology","length":81...